Literature DB >> 6850600

Isolation and characterization of subclones of L1210 murine leukemia with different sensitivities to various cytotoxic agents.

M Brouwer, L A Smets, A P Jongsma.   

Abstract

Two subclones of L1210 murine leukemia (L1210-46.1 and L1210-56.3) were isolated in the absence of selective agents. Subclone 56.3 appeared to be more sensitive than was subclone 46.1 to treatment with dexamethasone, 1-beta-D-arabinofuranosyl cytosine, vincristine, and X-irradiation. No differences between the parent cells and the two subclones could be observed in population-doubling time, cloning efficiency, number of chromosomes, and tumorigenic potential in DBA/2 mice. The subclones did not differ in the per cell number of glucocorticoid receptor sites. Animal experiments revealed an increase in life span of 65% in mice inoculated with cells from subclone 46.1 and of 130% of mice with subclone 56.3 after treatment with 1-beta-D-arabinofuranosylcytosine. The present results indicate that the L1210 wild-type murine leukemia cells contained stable subpopulations with a different but collateral sensitivity to various cytotoxic treatments. It is postulated that differences in drug sensitivity between cells are partly determined by cellular properties which are independent of the mechanism of action of any specific treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850600

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse.

Authors:  E Schäfer; B Maurer-Schultze
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Authors:  Andries M Bergman; Auke D Adema; Jan Balzarini; Skjalg Bruheim; Iduna Fichtner; Paul Noordhuis; Oystein Fodstad; Finn Myhren; Marit L Sandvold; Hans R Hendriks; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2010-01-12       Impact factor: 3.850

3.  Development of drug resistance in a murine mammary tumour.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

4.  Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.